Demographic and disease characteristics in the enrolled set (N = 20)
Characteristic . | N (%) . |
---|---|
Age, y | |
Mean | 61.5 |
Standard deviation | 12.5 |
Range | 39-80 |
Sex | |
Male | 10 (50) |
Female | 10 (50) |
Initial histology (local) | |
CD20+ FL grade 1 | 9 (45) |
CD20+ FL grade2 | 7 (35) |
CD20+ FL grade 3a | 1 (5) |
CD20+ FL (grade unknown) | 3 (15) |
No. of prior treatments | |
Median | 2.0 |
Range | 1-5 |
Ann Arbor stage | |
1-2 | 3 (15) |
3-4 | 17 (85) |
Performance status (ECOG) | |
0 | 16 (80) |
1 | 4 (20) |
Bone marrow involvement | 6 (40)* |
LDH, IU/L | |
Normal | 13 (65) |
>Upper limit of normal | 7 (35) |
Bulk >5 cm | |
No | 15 (75) |
Yes | 5 (25) |
Calculated FLIPI score | |
0 | 2 (10) |
1 | 3 (15) |
2 | 6 (30) |
3 | 7 (35) |
4 | 1 (5) |
5 | 1 (5) |
Refractory to rituximab | |
No | 12 (60) |
Yes | 8 (40) |
Refractory to prior lymphoma therapy | |
No | 16 (80) |
Yes | 4 (20) |
Characteristic . | N (%) . |
---|---|
Age, y | |
Mean | 61.5 |
Standard deviation | 12.5 |
Range | 39-80 |
Sex | |
Male | 10 (50) |
Female | 10 (50) |
Initial histology (local) | |
CD20+ FL grade 1 | 9 (45) |
CD20+ FL grade2 | 7 (35) |
CD20+ FL grade 3a | 1 (5) |
CD20+ FL (grade unknown) | 3 (15) |
No. of prior treatments | |
Median | 2.0 |
Range | 1-5 |
Ann Arbor stage | |
1-2 | 3 (15) |
3-4 | 17 (85) |
Performance status (ECOG) | |
0 | 16 (80) |
1 | 4 (20) |
Bone marrow involvement | 6 (40)* |
LDH, IU/L | |
Normal | 13 (65) |
>Upper limit of normal | 7 (35) |
Bulk >5 cm | |
No | 15 (75) |
Yes | 5 (25) |
Calculated FLIPI score | |
0 | 2 (10) |
1 | 3 (15) |
2 | 6 (30) |
3 | 7 (35) |
4 | 1 (5) |
5 | 1 (5) |
Refractory to rituximab | |
No | 12 (60) |
Yes | 8 (40) |
Refractory to prior lymphoma therapy | |
No | 16 (80) |
Yes | 4 (20) |
ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactic dehydrogenase.
n = 15.